scholarly journals Clinical significance of caspase-3 expression in pathologic-stage I, nonsmall-cell lung cancer

2001 ◽  
Vol 96 (S1) ◽  
pp. 54 ◽  
Author(s):  
Tetsuya Takata ◽  
Fumihiro Tanaka ◽  
Tomoko Yamada ◽  
Kazuhiro Yanagihara ◽  
Yosuke Otake ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Significance ◽  
Cell Lung Cancer ◽  
Caspase 3 ◽  
Nonsmall Cell Lung Cancer ◽  
Stage I ◽  
Pathologic Stage

Clinical significance of nm23 expression in resected pathologic-stage I, non-small cell lung cancer

2002 ◽  
Vol 73 (4) ◽  
pp. 1060-1064 ◽  
Author(s):  
Hiromichi Katakura ◽  
Fumihiro Tanaka ◽  
Hiroki Oyanagi ◽  
Ryo Miyahara ◽  
Kazuhiro Yanagihara ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Clinical Significance ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage I ◽  
Small Cell Lung ◽  
Pathologic Stage

scholarly journals Management of stage I and II nonsmall cell lung cancer

2016 ◽  
Vol 49 (1) ◽  
pp. 1600764 ◽  
Author(s):  
Fiona McDonald ◽  
Michèle De Waele ◽  
Lizza E. L. Hendriks ◽  
Corinne Faivre-Finn ◽  
Anne-Marie C. Dingemans ◽  
...  
Keyword(s):  
Lung Cancer ◽  
High Risk ◽  
Adjuvant Chemotherapy ◽  
Cell Lung Cancer ◽  
Targeted Therapies ◽  
Nonsmall Cell Lung Cancer ◽  
Stage I ◽  
Ageing Population ◽  
Randomised Trials ◽  
Long Term Outcome

The incidence of stage I and II nonsmall cell lung cancer is likely to increase with the ageing population and introduction of screening for high-risk individuals. Optimal management requires multidisciplinary collaboration. Local treatments include surgery and radiotherapy and these are currently combined with (neo)adjuvant chemotherapy in specific cases to improve long-term outcome. Targeted therapies and immunotherapy may also become important therapeutic modalities in this patient group. For resectable disease in patients with low cardiopulmonary risk, complete surgical resection with lobectomy remains the gold standard. Minimally invasive techniques, conservative and sublobar resections are suitable for a subset of patients. Data are emerging that radiotherapy, especially stereotactic body radiation therapy, is a valid alternative in compromised patients who are high-risk candidates for surgery. Whether this is also true for good surgical candidates remains to be evaluated in randomised trials. In specific subgroups adjuvant chemotherapy has been shown to prolong survival; however, patient selection remains important. Neoadjuvant chemotherapy may yield similar results as adjuvant chemotherapy. The role of targeted therapies and immunotherapy in early stage nonsmall cell lung cancer has not yet been determined and results of randomised trials are awaited.

Stage I Nonsmall Cell Lung Cancer up to 3 cm in Diameter: Prognostic Factors

2004 ◽  
Vol 40 (3) ◽  
pp. 110-113 ◽  
Author(s):  
J. Padilla ◽  
V. Calvo ◽  
J.C. Peñalver ◽  
C. Jordá ◽  
J. Escrivá ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factors ◽  
Cell Lung Cancer ◽  
Nonsmall Cell Lung Cancer ◽  
Stage I

Women With Pathologic Stage I, II, and III Non-small Cell Lung Cancer Have Better Survival Than Men

CHEST Journal ◽  
2006 ◽  
Vol 130 (6) ◽  
pp. 1796-1802 ◽  
Author(s):  
Robert James Cerfolio ◽  
Ayesha S. Bryant ◽  
Ethan Scott ◽  
Manisha Sharma ◽  
Francisco Robert ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage I ◽  
Small Cell Lung ◽  
Pathologic Stage

Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer

Cancer ◽  
2009 ◽  
Vol 115 (4) ◽  
pp. 851-858 ◽  
Author(s):  
John M. Varlotto ◽  
Abram Recht ◽  
Margaret Nikolov ◽  
John C. Flickinger ◽  
Malcolm M. DeCamp
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Nonsmall Cell Lung Cancer ◽  
Stage I

scholarly journals Macrophage Inhibitory Cytokine-1 as a Novel Diagnostic and Prognostic Biomarker in Stage I and II Nonsmall Cell Lung Cancer

2016 ◽  
Vol 129 (17) ◽  
pp. 2026-2032 ◽  
Author(s):  
Yu-Ning Liu ◽  
Xiao-Bing Wang ◽  
Teng Wang ◽  
Chao Zhang ◽  
Kun-Peng Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Prognostic Biomarker ◽  
Nonsmall Cell Lung Cancer ◽  
Stage I

The risk of second primary tumors after resection of stage I nonsmall cell lung cancer

2003 ◽  
Vol 76 (4) ◽  
pp. 1001-1008 ◽  
Author(s):  
David Rice ◽  
Hyung-Woo Kim ◽  
Anita Sabichi ◽  
Scott Lippman ◽  
J.Jack Lee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Nonsmall Cell Lung Cancer ◽  
Stage I ◽  
Second Primary ◽  
Primary Tumors ◽  
Second Primary Tumors
Sign in / Sign up

Export Citation Format

Share Document